• Ryan Kelly

FDA Approve INSPIRE by Barnard Health : Landmark Decision

Updated: Jun 27

Principal Investigator Katharine Barnard-Kelly received notice from the US Food and Drugs Agency confirming the award of MDDT qualification of the novel INSPIRE psychosocial measures. This landmark decision, the first ever diabetes-related Medical Device Development Tool, demonstrates the importance the FDA place on psychosocial outcomes alongisde biomedical outcomes, as well as the very high standards of scientific rigour Prof Barnard-Kelly and her team executed throughout the project.

The FDA announcement:

Also, coverage from Close Concerns:


(+44) 07703641048

  • Twitter
  • LinkedIn

All Rights Reserved ©2020 Barnard Health Research Limited.